Developmental trajectories in infants and pre-school children with Neurofibromatosis 1.

Developmental trajectories in infants and pre-school children with Neurofibromatosis 1.

Publication date: Oct 15, 2024

Children with Neurofibromatosis 1 (NF1) show cognitive, behavioural and social differences compared to their peers. However, the age and sequence at which these differences begin to emerge is not fully understood. This prospective cohort study examines the cognitive, behavioural, ADHD trait and autism symptom development in infant and pre-school children with NF1 compared with typically developing (TD) children without a family history of neurodevelopmental conditions. Data from standardised tests was gathered at 5, 10, 14, 24 and 36 months of age (NF1 nā€‰=ā€‰35, TD nā€‰=ā€‰29). Developmental trajectories of cognitive (Mullen Scales of Early Learning, MSEL) and adaptive behavioural (Vineland Adaptive Behavior Scales, VABS) development from 5 to 36 months were analysed using linear mixed modelling. Measures of ADHD (Child Behavior Checklist) and autism traits (ADOS-2, BOSA-MV and ADI-R) were assessed at 24 and 36 months. The developmental trajectory of cognitive skills (all domains of the MSEL) and behavioural skills (four domains of the VABS) differed significantly between NF1 and TD groups. Post-hoc tests demonstrated that the NF1 participants scored significantly lower than TD participants at 24 months on all MSEL and VABS domains. The NF1 cohort demonstrated higher mean autism and ADHD traits at 24 months and 14% of the NF1 cohort met a research diagnostic classification for autism at 36 months. The study has a relatively small sample size due to variable retention and rolling recruitment. Due to limitations imposed by the COVID-19 pandemic, we utilised the Brief Observation of Symptoms of Autism for Minimally Verbal children (BOSA-MV) for some participants, which was administered online and may not gather as accurate a picture of traits as ADOS-2. The BOSA-MV was utilised for 41% of participants with NF1 at 36 months compared to 11% at 24 months. This may explain the reduction in the percentage of children with NF1 that met autism criteria at 36 months. By 24 months of age, the NF1 cohort show lower cognitive skills and adaptive behaviour and higher levels of autism and ADHD traits as compared to TD children. This has implications for developmental monitoring and referral for early interventions. Not applicable.

Open Access PDF

Concepts Keywords
24months ADHD
Autism Autism
Covid Children
Neurofibromatosis Cohort
Recruitment Neurofibromatosis
NF1
Trajectories

Semantics

Type Source Name
disease MESH Neurofibromatosis 1
disease MESH ADHD
disease MESH autism
disease IDO symptom
drug DRUGBANK Methionine
disease MESH COVID-19 pandemic
pathway REACTOME Reproduction
disease MESH Neurofibromatosis
disease IDO history
disease MESH phenotypic variability
disease MESH Autism Spectrum Disorder
drug DRUGBANK Coenzyme M
disease IDO intervention
drug DRUGBANK Isoxaflutole
disease MESH complications
disease MESH visual impairments
drug DRUGBANK Trestolone
disease IDO algorithm
disease MESH abnormalities
drug DRUGBANK Esomeprazole
disease IDO role
drug DRUGBANK Piroxicam
drug DRUGBANK Gold
disease MESH Noonan syndrome
disease MESH cardiofaciocutaneous syndrome
disease IDO replication
disease MESH Amelia
disease MESH tumor
disease MESH syndromes
disease MESH Legius syndrome
disease MESH comorbidity
pathway REACTOME Pervasive developmental disorders
disease MESH neurodevelopmental disorders
drug DRUGBANK Dopamine
disease MESH neurofibroma
disease MESH dual diagnosis
disease MESH plexiform neurofibromas
disease MESH mental disorders

Original Article

(Visited 1 times, 1 visits today)